John Gill, director of cell-line development, Samsung Biologics Samsung Biologics has expanded its capabilities with a goal of providing end-to-end biomanufacturing solutions. The company has offered both drug-substance (DS) and drug-product (DP) manufacturing services since its inception. Across three sites in South Korea, the company offers 364,000 L of bioreactor capacity, including units for n – 1 perfusion cell culture. To those capabilities Samsung has added contract research support for biosafety testing, standalone quality control (QC) services, and a novel cell-line development…

Tatiana Golovina, senior director, cell therapy process development, WuXi Advanced Therapies Golovina described recent developments at WuXi Advanced Therapies, a unit within WuXi AppTec that specializes in developing and manufacturing cell and gene therapies (CGTs). Until recently, the Advanced Therapies business operated over three sites at the US Navy Yard in Philadelphia, PA. Those facilities focus on CGT clinical manufacturing, commercial manufacturing for autologous and allogeneic cell therapies, and late-stage and commercial production of viral vectors and gene-mediated cell therapies,…

Alex Satz, senior director, DEL strategy and operations, WuXi AppTec Satz talked about WuXi AppTec’s launch of the HitS (Hit Success) business unit, designed to serve client needs in early stage drug discovery. WuXi’s goals are to provide more and higher-quality hit molecules against targets of interest and to help set the stage for follow-up medical-chemistry optimization. The unit works with all protein target classes, including solubilized membrane proteins and challenging protein complexes. A core strength of the HitS business…

Gregory Bleck, PhD, global head of R&D, biologics, Catalent Catalent’s GPEx Boost technology, based on the company’s GPEx technology, is used for engineering high-expressing Chinese hamster ovary (CHO) cells for pharmaceutical production. Using replication and retrovector technology, genes are inserted into mammalian cell lines. The process requires neither antibiotic selection nor use of toxic compounds for gene amplification to make genetically stable cell lines, so stability testing can be kept off of the critical path for some programs. To date,…

Yong Cang, professor of cancer cell biology, Shanghai Tech University (China) and scientific advisor, WuXi AppTec Because cancer is a genetic disease, Cang observed, researchers are trying systematically to identify genes that enable cancerous propagation. That often requires studying how familiar genes are expressed in vitro. But such cellular behavior can change under different experimental conditions: e.g., when cells are cultured in two- or three-dimensional bioreactors and when studies involve therapeutic compounds or T cells. Cang suggested that researchers might be…

Richard W. Welch, PhD, vice president of development services, Emergent BioSolutions Welch focused on elements of pandemic preparedness. Emergent has a history of working with the US government on bioterrorism and biodefense preparedness, with a focus in recent years on developing platform-based responses to emerging disease threats. Emergent is focusing on therapeutics and vaccines to respond to COVID-19. The company’s therapeutic business unit uses the company’s internal hyperimmune process to generate therapeutics from the plasma of recovering donors, leveraging an…

Jerry Yang, senior vice president and general manager, HJB International Yang introduced his company, HJB, as an integrated contract and development manufacturing organization (CDMO) with business centers in Boston, San Francisco, and Shanghai. The manufacturing site in Hangzhou City is about an hour-long drive from Shanghai City. The company’s mission is to maintain a global quality business standard, developing innovative technology to balance low costs with high quality, and to serve as a flexible, efficient, and reliable partner. Integrated platforms…

Jonathan Freeman, PhD, founder and COO, Anthos Therapeutics, and senior advisor, Blackstone Life Sciences; and Abdelaziz Toumi, PhD, head of Ibex design and development, customer solutions, Lonza Pharma & Biotech Freeman spoke about the history and philosophy of Anthos and its core program, focusing on specific needs of virtual biotechnology companies particularly from an investor standpoint. Anthos was created after the formation of Blackstone Life Sciences, in collaboration with Novartis. Blackstone’s goal is to find innovative financing approaches that enable…

Jeremy Rautenbach, global product manager, Biotech Integrated Solutions, Pall Biotech  Rautenbach emphasized the importance of timely decision-making in the context of viral vector manufacturing. He stressed the importance of quantifying requirements for biomanufacturing skills early in a process and showed how platform approaches can accelerate market entry and reduce risks to ensure manufacturing readiness at the point of approval. Key operational decisions can be well-informed, planned for, and executed by the time a drug is intended to be approved. Committing…

Richard Lee, head of the drug product business unit, Samsung Biologics Lee spoke about the evolution of drug-product contract manufacturing and how the business has transformed in response to the ongoing coronovirus pandemic. He spoke about how COVID-19 affected life in South Korea described changes his company has made in how it approached sales, technology transfer, and manufacturing operations. As he put it, “Everything has changed.” South Korea was one of the first affected countries from China’s initial outbreak. Its…